

ANNUAL FINANCIAL STATEMENTS

86

**BALANCE SHEET AS OF
31 DECEMBER 2021**

88

**STATEMENT OF
PROFIT AND LOSS
FOR THE 2021
FINANCIAL YEAR**

90

**NOTES TO THE
FINANCIAL STATEMENTS
FOR THE 2021
FINANCIAL YEAR**

118

**STATEMENT OF CHANGES
IN FIXED ASSETS
AS OF 31 DECEMBER 2021**

120

**INDEPENDENT
AUDITORS REPORT**

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin

BALANCE SHEET AS OF 31 DECEMBER 2021

ASSETS	EUR	EUR	EUR	31.12.2021 EUR	31.12.2020 TEUR
A. Fixed assets					
I. Intangible assets					
1. Purchased concessions, industrial property rights and similar rights and assets, as well as licences to such rights and assets		11,658,278.67			9,280
2. Prepayments made		1,508,167.76			2,602
			13,166,446.43		11,882
II. Tangible fixed assets					
1. Land, rights equivalent to land, and buildings including buildings on third-party land		1,177,284,518.35			1,195,147
2. Technical plant and machinery		473,884,118.38			495,926
3. Other plant, operating and office equipment		163,162,342.88			183,425
4. Prepayments made and plant under construction		358,388,844.91			312,453
			2,172,719,824.52		2,186,951
III. Financial assets					
1. Shares in affiliated companies		608,200.00			608
2. Participations		288,076.97			288
3. Investment securities		151,526,314.73			137,453
4. Other loans and shares		2,632,611.67			2,470
			155,055,203.37		140,819
				2,340,941,474.32	2,339,652
B. Current assets					
I. Inventories					
1. Research materials		10,920,696.54			10,782
2. Other materials		965,166.71			1,011
3. Work-in-progress		2,088.00			1
			11,887,951.25		11,794
II. Receivables and other assets					
1. Trade receivables		5,544,168.21			7,674
2. Receivables due from funding providers					
a) from institutional funding	155,014,068.86				93,179
b) from project funding	26,061,655.32				26,597
c) from compensation claims	822,183,926.64				778,686
		1,003,259,650.82			898,462
3. Receivables due from affiliated companies		22,784,442.04			21,092
4. Receivables due from companies in which an equity interest is held		0.00			71
5. Other assets		13,811,826.27			35,118
			1,045,400,087.34		962,417
III. Securities					
1. Shares in affiliated companies		27,000.00			27
2. Other securities		1,733,798.35			1,511
			1,760,798.35		1,538
IV. Cash in hand, bank balances and cheques			182,979,949.94		137,986
				1,242,028,786.88	1,113,735
C. Deferred expenses and accrued income				43,346,750.66	40,704
TOTAL				3,626,317,011.86	3,494,091
<i>for information purposes:</i> Trust assets				70,599,294.48	105,800

EQUITY AND LIABILITIES

	EUR	EUR	EUR	31.12.2021 EUR	31.12.2020 TEUR
A. Equity					
I. Association capital			166,425,181.13		160,169
II. Reserves for statutory purposes			29,939,925.97		27,564
III. Result carried forward			978,497.18		1,750
				197,343,604.28	189,483
B. Extraordinary item					
1. From subsidies for fixed assets			2,148,368,462.29		2,173,058
2. From subsidies for current assets			73,583,847.44		68,634
				2,221,952,309.73	2,241,692
C. Provisions					
1. Provisions for pensions and similar obligations			730,678,629.00		663,403
2. Tax provisions			317,942.00		0
3. Other provisions			103,056,381.44		109,180
				834,052,952.44	772,583
D. Liabilities					
1. Bank borrowings			532,896.44		550
2. Trade payables			51,955,309.07		48,042
3. Liabilities to funding providers					
a) from institutional funding		169,324,301.52			108,572
b) from project funding		122,655,068.98			105,202
			291,979,370.50		213,774
4. Liabilities due to affiliated companies			4,900,000.00		5,039
5. Liabilities due to companies in which an equity interest is held			70,299.58		19
6. Other liabilities			22,843,377.29		21,435
– of which from tax:		12,258,570.76			
		(31.12.2020: 12,651,728.31)			
– of which as part of social security:		2,706,842.14			
		(31.12.2020: 2,571,628.26)			
				372,281,252.88	288,859
E. Deferred income and accrued expenses				686,892.53	1,474
TOTAL				3,626,317,011.86	3,494,091
<i>for information purposes:</i>					
Trust liability				70,599,294.48	105,800

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin

STATEMENT OF PROFIT AND LOSS FOR THE 2021 FINANCIAL YEAR

	EUR	EUR	2021 EUR	Previous year TEUR
1. Subsidies from institutional funding				
1.1 Basic funding		1,954,284,827.00		1,892,901
1.2 Partial special funding		9,150,000.00		26,000
1.3 Special funding		4,100,000.00		3,330
1.4 Other partial special funding		1,937,362.00		1,894
			1,969,472,189.00	1,924,125
2. Changes in receivables due from funding providers deriving from compensation claims (increase/(-) decrease)			43,497,973.69	63,925
3. Own revenues and other income				
3.1 Income from research and development and from utilization of research facilities		2,918,806.30		3,623
3.2 Income from licence and know-how agreements		18,696,392.72		20,759
3.3 Income from infrastructure services and sales of materials		19,970,644.19		25,421
3.4 Rental and lease income		12,043,600.95		11,539
3.5 Income from fixed asset disposals		5,456,618.10		5,441
3.6 Increase/(-) decrease in work-in-progress		0.00		0
3.7 Other work performed by the enterprise and capitalized		5,901,221.64		6,421
3.8 Financial income, income from participating interests, interest income		3,250,839.57		3,835
3.9 Other operating income		206,483,126.76		178,298
			274,721,250.23	255,337
4. Subsidies from project funds			275,985,378.95	302,797
5. Income from release of extraordinary items (loan repayment)			71,741.20	81
carried forward			2,563,748,533.07	2,546,265

	EUR	EUR	2021 EUR	Previous year TEUR
carried forward			2,563,748,533.07	2,546,265
6. Personnel expenses				
6.1 Wages and salaries		990,858,924.66		993,344
6.2 Social security contributions and expenses for pensions and benefits		325,439,100.58		306,615
– of which for pensions:	118,601,417.90 (previous year: 95,830,390.77)			
			1,316,298,025.24	1,299,959
7. Costs of materials				
7.1 Expenses for raw materials, consumables and supplies, and for purchased goods		190,088,679.02		197,515
7.2 Expenses for purchased services		10,432,124.25		14,552
			200,520,803.27	212,067
8. Change in the extraordinary item for current assets (increase/(-) decrease)				
			4,769,491.37	-11,100
9. Depreciation and amortization of intangible and tangible fixed assets				
9.1 Depreciation and amortization of intangible and tangible fixed assets		339,511,703.68		341,539
9.2 Income from release due to amortization and depreciation of extraordinary items for intangible and tangible fixed assets		338,345,992.11		340,557
			1,165,711.57	982
10. Other expenses				
10.1 Interest and similar expenses		14,184,669.18		15,306
– of which from the reversal of discounts to provisions:	14,181,942.25 (previous year: 15,303,321.38)			
10.2 Other operating expenses		654,123,476.65		599,279
			668,308,145.83	614,585
11. Transfers and subsidies granted				
			44,462,671.69	53,123
12. Expenses from addition to the extraordinary item (subsidized investments)				
12.1 to finance intangible and tangible fixed assets		320,180,130.99		367,105
12.2 to finance financial assets and shares in spin-offs		182,690.22		183
			320,362,821.21	367,288
13. Annual result				
			7,860,862.89	9,361
14. Result carried forward from the previous year				
			1,750,057.02	2,562
15. Withdrawals from the association capital				
			4,056,122.24	2,548
16. Withdrawals from reserves for statutory purposes				
			2,539,718.32	2,175
17. Allocations to association capital				
			-10,312,624.04	-10,065
18. Allocations to reserves for statutory purposes				
			-4,915,639.25	-4,831
19. Result carried forward				
			978,497.18	1,750

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin

NOTES TO THE FINANCIAL STATEMENTS FOR THE 2021 FINANCIAL YEAR

of the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin
Register of Societies No. VR 13378 B, Berlin-Charlottenburg District Court


1. General information on the Annual Financial Statements

The annual financial statements of the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (hereafter „MPG“) were prepared in analogous application of the regulations of the Third Book of the German Commercial Code (HGB) for large corporations with due consideration given to association law.

The annual financial statements of MPG include the following accounting entities:

- Legally dependent Institutes and research units as well as central institutions
- “Assets not publicly funded” (hereafter NÖV)
- Operations pursuant to §26 of the Federal Budget Ordinance (BHO) (including the MPI for Psychiatry)
- Max Planck Institute for Plasma Physics (hereafter IPP)

Together with the legally independent Max Planck Institutes (the Max-Planck-Institut für Eisenforschung Gesellschaft mit beschränkter Haftung and the Max-Planck-Institut für Kohlenforschung (rechtsfähige Stiftung)), the MPG excluding IPP forms a consortium of applicants which is the recipient of joint institutional funding from the federal administration and federal states. Since 01 Januar 2021 IPP belongs to the consortium of applicants.¹ The annual financial statements of the legally independent Institutes are not included in the annual financial statements of the MPG.



¹The IPP was an associate member of the Helmholtz Association until 31 December 2020.

The "assets not publicly funded" represent assets belonging to the MPG made up of private third-party funds which are managed with due regard for intended purpose, tax regulations and public funding law. The MPG generates income from these assets, which is used for the promotion of research. In the explanations on individual items on the assets side of the balance sheet, the share of assets not publicly funded is identified by applying a further breakdown of figures.

Advantage was taken of the options afforded under § 265 paras. 5 to 7 HGB in order to reflect the particularities specific to the sector and legal form of MPG as a research facility, and to ensure a clear, transparent presentation. On the one hand, the designation and structure of the items of the balance sheet and of the statement of profit and loss were adjusted, and on the other, items in the profit and loss account were combined. In accordance with the budget of the MPG, scholarships for supported junior personnel are shown under personnel expenses.

2. Accounting Policies

Intangible and tangible fixed assets are measured at their costs of purchasing or manufacturing on the date of addition. For subsequent valuation, they are amortized and depreciated exclusively applying the straight-line method. For this purpose, the MPG applies a generalized useful life specific to asset class.

Low-value assets with costs of purchasing and manufacturing up to EUR 800 (net) inclusive are fully expensed in special accounts in the year of purchase.

Financial assets are recognized at purchase cost. Financial assets are written down to the lower of cost or fair value given prospectively permanent impairment.

The research materials shown under inventories and other materials are recognized at the lower of cost or fair value.

Work-in-progress includes work conducted by IPP – measured on the basis of unit costings - which, as well as directly attributable costs of materials, wage costs and special costs, also including appropriate portions of production and materials overheads as well as the asset erosion of the utilized fixed assets.

Receivables and other assets are recognized at the lower of nominal or fair value. No generalized valuation allowances have been applied due to the minor portfolio of receivables, which is generally to be regarded as collectible.

Liquid funds are measured at nominal value.

Current bank balances denominated in foreign currencies were translated at the spot mid exchange rate on the balance sheet date in accordance with § 256a HGB.

Accruals and deferrals are formed in accordance with the principles of periodic allocation.

Equity is reported based on the IDW accounting standard "Accounting for associations" (IDW RS HFA 14).

The MPG receives funding from the public sector and other third parties. Where these have been used for the purchase or production of fixed assets requiring capitalization, they have been recognized as liabilities in the form of an extraordinary item from subsidies for fixed assets, and are not offset with costs of purchasing or manufacturing (gross method). This does not apply to assets of the NÖV.

Similarly, the extraordinary item from subsidies for current assets reflects the current assets financed through institutional or project funding.

Provisions are formed for all identifiable risks and contingent obligations, taking due account of the probable utilization at the settlement amount required on the basis of prudent commercial judgement. Future increases in prices and costs are taken into account if sufficient objective indications exist that they will occur. Provisions are discounted in accordance with § 253 para. 2 HGB if their residual term is more than one year, in other words, applying the average market interest rate corresponding to the residual term, derived in the case of pension provisions over the past ten financial years, and in the case of other provisions from the past seven financial years. Income or expenses resulting from changes in the discount rate, or the interest effects of a change in the estimate of the residual term, are shown in personnel expenses or in other operating expenses, depending on the provision type.

Pension provisions have been calculated based on an independent actuarial report in accordance with the accrued funding method, taking into account the 2018 G Mortality Tables of Prof. Dr. Heubeck. A trend of 1.50% (previous year 1.50%) was assumed for both salaries and pensions. The average market interest rate for the past ten years of 1.87% (previous year 2.30%) was applied for the discounting for a generalized residual term of 15 years. The discounting applying the average market interest rate for the past ten years generates a difference of EUR 46,393,720 (previous year 55,694,489) compared with discounting applying the average market rate for the past seven years (1.35%).

Provisions for aid obligations have been calculated based on an independent actuarial report in accordance with the accrued funding method, taking into account the current probability tables (average insurance payout statistics [Kopfschadenstatistiken]) in private health insurance for 2020, as published by the German Federal Financial Supervisory Authority (BaFin), as well as the 2018 G Mortality Tables of Prof. Dr. Heubeck. This entailed taking as a basis an average market interest rate for the past seven years of 1.35% (previous year 1.60%) for a generalized residual term of 15 years and a benefit trend of 2.00% (previous year 2.00%).

The partial retirement provision was determined by means of an independent actuarial report taking into account the 2018 G Mortality Tables of Prof. Dr. Heubeck. As well as settlement arrears, the calculation includes the complete amounts above the current salary in existing partial retirement arrangements. The calculation was based on an average market interest rate from the last seven years of 0.34% corresponding to the residual term (previous year 0.49%), 0.49% for IPP (previous year 0.64%) as well as a salary trend of 1.50% (previous year 1.50%).

The anniversary obligation provision was determined by means of an independent actuarial report based on the projected unit credit method taking into account the 2018 Mortality Tables of Prof. Dr. Heubeck, an actuarial interest rate of 1.35% (previous year 1.60%) for a generalized residual term of 15 years, and a salary trend of 1.50% (previous year 1.50%).

Liabilities are recognized at their settlement amount.

Receivables and liabilities denominated in foreign currencies are translated on the balance sheet date at the spot mid exchange rate.

Trust assets essentially comprise trust-administered EU project funds. They are matched by corresponding trust liabilities.

The statement of profit and loss is complemented by a statement showing the application of results.

3. Explanations and notes to the balance sheet

3.1 Fixed assets

Changes in individual items of fixed assets are shown in the annex to the notes to the financial statements in the statement of changes in fixed assets.

Intangible assets

	31.12.2021 TEUR	<i>of which NÖV</i>	31.12.2020 TEUR
INTANGIBLE ASSETS			
Purchased concessions, industrial property rights and similar rights and assets, as well as licences to such rights and assets	11,658	16	9,280
Prepayments made	1,508	0	2,602
TOTAL	13,166	16	11,882

Intangible assets essentially comprise software licences.

The MPG does not make use of the capitalization option for internally generated intangible assets pursuant to §248 para. 2 HGB.

Tangible fixed assets

	31.12.2021 TEUR	<i>of which NÖV</i>	31.12.2020 TEUR
TANGIBLE FIXED ASSETS			
Land, rights equivalent to land, and buildings including buildings on third-party land	1,177,285	35,604	1,195,147
Technical plant and machinery	473,884	0	495,926
Other plant, operating and office equipment	163,162	1,165	183,425
Prepayments made and plant under construction	358,389	769	312,453
TOTAL	2,172,720	37,538	2,186,951

The following large-scale construction projects were, among other items, capitalized in the reporting year after completion:

	TEUR
MPI of Psychiatry, München, new Institute building Preclinical Center	20,388
MPI of Microstructure Physics, Halle, new Institute building TEM	2,754

The item **technical plant and machinery** comprises essentially the scientific equipment and devices as well as operating facilities (mainly fixed installations in laboratories, animal facilities and greenhouses), produced as part of the construction projects.

The item **other plant, operating and office equipment** is comprised as follows on the balance sheet date:

	31.12.2021 TEUR	31.12.2020 TEUR
Other plant, operating and office equipment		
Facility and IT equipment	123,062	141,778
Libraries	38,656	40,073
Vehicles	1,444	1,574
TOTAL	163,162	183,425

The increase in **prepayments made and plant under construction** is essentially the result of expenditure for construction projects before completion.

Financial assets

	31.12.2021 TEUR	of which NÖV	31.12.2020 TEUR
FINANCIAL ASSETS			
Shares in affiliated companies	608	526	608
Participations	288	238	288
Investment securities	151,526	151,526	137,453
Other loans and shares	2,633	2,129	2,470
TOTAL	155,055	154,419	140,819

There were no indications of prospectively permanent impairment as of the balance sheet date.

The reported participations serve the MPG as part of its statutory purpose to establish long-term science-driven cooperation.

The **securities held as fixed assets** are exclusively attributable to the NÖV. The increase in the level of securities investments compared with the previous year is mainly due to legacies.

Other loans and shares contain loans for housebuilding funding (family home loans) amounting to TEUR 2,616 as well as other loans (TEUR 17).

An overview of shareholdings can be found in note 5 Other disclosures of these notes to the financial statements.

3.2 Current assets

Inventories

Inventories comprise assets which are not serving operations on a continuing basis and are purchased for consumption. As the MPG conducts basic research, instead of the raw materials, consumables and supplies closely associated with production manufacturing, the materials required for research are reported and divided as follows within inventories:

	31.12.2021 TEUR	of which NÖV	31.12.2020 TEUR
INVENTORIES			
Research materials	10,921	0	10,782
Other materials	965	31	1,011
Work-in-progress	2	0	1
TOTAL	11,888	31	11,794

Receivables and other assets

	31.12.2021 TEUR	of which NÖV	31.12.2020 TEUR
RECEIVABLES AND OTHER ASSETS			
Trade receivables	5,544	74	7,674
Receivables due from funding providers	1,003,260	0	898,462
Receivables due from affiliated companies	22,784	0	21,092
Receivables due from companies in which an equity interest is held	0	0	71
Other assets	13,812	4,129	35,118
TOTAL	1,045,400	4,203	962,417

Trade receivables relate in an amount of TEUR 4,311 (31 December 2020: TEUR 4,435) to receivables from hospital services of the MPI for Psychiatry.

	31.12.2021 TEUR	31.12.2020 TEUR
Receivables due from funding providers		
from institutional funding	155,014	93,179
from project funding	26,062	26,597
from compensation claims	822,184	778,686
TOTAL	1,003,260	898,462

Receivables due from funding providers from institutional funding essentially represent receivables for approved funding in the reporting year whose multi-year availability is established by the budget instrument of funds managed under own responsibility (Selbstbewirtschaftung). This position contains funds managed under own responsibility for the federal administration and its federal states, in the amount of TEUR 143,926, of which TEUR 6,000 for IPP (previous year TEUR 82,041, of which TEUR 5,925). Also shown here are claims to additional payments from federal states resulting from the final calculation by the MPG of fund distribution, which in principle are to be paid in the third year following billing (TEUR 9,928); of this amount, TEUR 5,265 has a residual term of over one year.

Receivables due from funding providers from project funding include project funding expenditure covered by funding approval letters from third-party funding bodies if the third-party funds have not yet been received.

Receivables due from funding providers from compensation claims form the counterpart, in principle, to obligations entered into on the basis of a funding relationship and not covered by funds in the current financial year (No. 4 (2) of the Management Principles for the MPG (BewGr-MPG)). They are comprised as follows as on the reporting date:

	TEUR
MPG excluding IPP	800,354
IPP	21,830

Of the compensation claims, a total of TEUR 744,058 (previous year TEUR 676,741) have a residual term of over one year.

Receivables due from affiliated companies relate mainly to receivables due from Max-Planck-Innovation GmbH deriving from licence income and one loan granted to MPDL Services gGmbH.

As of the balance sheet date, **other assets** include:

	TEUR
VAT receivables due from tax authorities	4,754
Claims from legacies (NÖV)	2,044
Receivables from investment securities (NÖV)	1,436
Shares in spin-offs held-for-disposal	1,375

Spin-offs are companies established to convert a technology or scientific know-how developed at a Max Planck Institute into products and services, among other objectives. Equity interests in spin-offs are held on the basis of guidelines for research facilities to participate in spin-offs for the purpose of the transfer of knowledge and technology published by the Federal Ministry of Education and Research.

Securities

	31.12.2021 TEUR	<i>of which NÖV</i>	31.12.2020 TEUR
SECURITIES			
Shares in affiliated companies	27	0	27
Other securities	1,734	237	1,511
TOTAL	1,761	237	1,538

The shares in affiliated companies are held for the MPDL Services gGmbH, München. The other securities are mainly part of an income from the disposal of shares in spin-offs of the year 2020.

Cash in hand, bank balances and cheques

	31.12.2021 TEUR	<i>of which NÖV</i>	31.12.2020 TEUR
Cash in hand, bank balances and cheques	182,980	1,914	137,986

As of the reporting date, the liquid funds position contains unutilized budget funds from institutional funding whose multi-year availability is established by other budget instruments outside of funds managed under own responsibility (Selbstbewirtschaftung), as well as funds from project funding which can also be transferred to the following year.

3.3 Deferred expenses and accrued income

	31.12.2021 TEUR	<i>of which NÖV</i>	31.12.2020 TEUR
Deferred expenses and accrued income	43,347	21	40,704

Deferred expenses and accrued income contain expenditure before the balance sheet date which will only be recognized after that date. This item mainly contains prepayments of licensing fees and usage fees for (online) media. Salary payments of TEUR 6,349 for January 2022 are included, which are due on 1 January 2022.

3.4 Trust assets

The trust assets include TEUR 69,434 of trust-administered EU project funds, of which TEUR 24,077 are attributable to IPP.

3.5 Equity

	31.12.2021 TEUR	31.12.2020 TEUR
EQUITY		
Association capital	166,425	160,169
Reserves for statutory purposes	29,940	27,564
Result carried forward	979	1,750
TOTAL	197,344	189,483

Equity is entirely accounted for by NÖV. Equity is reported with due consideration given to funding provider requirements and reflecting tax law regulations. Regarding the reserves, the specifications contained in the regulations of the German Fiscal Code (AO) have been implemented. The equity has increased by the annual result of TEUR 7,861.

Apart from NÖV, the annual financial statements of the MPG close without net profit or net loss for the year.

3.6 Extraordinary item

The extraordinary item is comprised as follows:

	31.12.2021 TEUR	31.12.2020 TEUR
EXTRAORDINARY ITEM		
from subsidies for fixed assets	2,148,368	2,173,058
from subsidies for current assets	73,584	68,634
TOTAL	2,221,952	2,241,692

The **extraordinary item from subsidies for fixed assets** reflects the fixed assets funded by public sector subsidies and subsidies from other third parties. Accordingly, no extraordinary item was formed for NÖV fixed assets and for an inheritable building right at the MPI for Psychiatry (TEUR 600), which is matched by a long-term liability. This results in the following table of extraordinary items and fixed assets as of the closing date:

	Fixed assets covered by extraordinary items	Fixed assets not covered by extraordinary items		Total fixed assets
	TEUR	NÖV TEUR	MPI for Psychiatry TEUR	TEUR
Intangible assets	13,150	16	0	13,166
Tangible fixed assets	2,134,582	37,538	600	2,172,720
Financial assets	636	154,419	0	155,055
TOTAL	2,148,368	191,973	600	2,340,941

The **extraordinary item from subsidies for current assets** reflects the current assets financed through institutional or project funding.

3.7 Provisions

Provisions for pensions and similar obligations are comprised as follows:

	1.1.2021 TEUR	Consumption TEUR	Release TEUR	Reversal of discount TEUR	Addition TEUR	31.12.2021 TEUR
Pension obligations	535,141	20,528	10,616	12,072	75,599	591,668
Aid obligations	128,262	3,061	2,339	2,028	14,121	139,011
TOTAL	663,403	23,589	12,955	14,100	89,720	730,679

Provisions for pensions and similar obligations are formed for benefit claims and entitlements for aid resulting from employment contracts similar to civil service contracts which may be concluded under the conditions pertaining to the Annex to No. 8 (1) BewGr-MPG. A total of 1,323 (previous year 1,315) entitled persons, of whom 678 active (previous year 685), are included in the provision for pension obligations as of the reporting date, and a total of 950 (previous year 897) entitled persons, of whom 484 active (previous year 460), are included in the provision for aid obligations. The interest expense shown derives from reversing the discount to the obligation at the beginning of the period applying the interest rate defined at this time, taking into consideration the interest portion of the pensions or aid paid to the beneficiaries in the reporting year. The increase in provisions for pensions and similar obligations results principally from the reduction in the actuarial interest rate on which the calculation is to be based, pursuant to § 253 para. 2 HGB.

The difference between discounting applying the average market interest rate for the past ten years and discounting applying the average market interest rate for the past seven years amounts to TEUR 46,394 (previous year TEUR 55,694) for the provisions for pension obligations as of the reporting date.

The **tax provisions** amount to TEUR 317 as of the balance sheet date (Vorjahr 0 TEUR).

Other provisions are comprised as follows:

	1.1.2021 TEUR	Consumption TEUR	Release TEUR	Reversal of discount TEUR	Addition TEUR	31.12.2021 TEUR
Remaining vacation	66,333	66,333	0	0	59,597	59,597
Invoices outstanding	17,678	17,678	0	0	17,371	17,371
Partial retirement	7,434	2,669	0	38	3,024	7,827
Overtime/time credits	6,887	3,041	0	0	3,355	7,201
Archiving costs	3,435	0	335	0	0	3,100
Service anniversaries	2,469	151	180	31	284	2,453
Legal costs	1,034	49	611	0	266	640
Travel costs not yet invoiced	249	249	0	0	681	681
Miscellaneous other provisions	3,661	1,242	433	13	2,187	4,186
TOTAL	109,180	91,412	1,559	82	86,765	103,056

Besides short-term flexi-time credits, provisions for overtime/time credits also include longer-term working time accounts in an amount of TEUR 3,608.

3.8 Liabilities

	31.12.2021 TEUR	31.12.2020 TEUR
LIABILITIES		
Bank borrowings	533	550
Trade payables	51,955	48,042
Liabilities to funding providers	291,979	213,774
Liabilities due to affiliated companies	4,900	5,039
Liabilities due to companies in which an equity interest is held	70	19
Other liabilities	22,844	21,435
TOTAL	372,281	288,859

Bank borrowings relate entirely to NÖV.

Trade payables mainly contain typical liabilities from supplies and services. They also include warranty retentions of TEUR 649 (previous year TEUR 664).

	31.12.2021 TEUR	31.12.2020 TEUR
Liabilities to funding providers		
from institutional funding	169,324	108,572
from project funding	122,655	105,202
TOTAL	291,979	213,774

Pursuant to No. 5 of the Management Principles for the MPG (BewGr-MPG), the multi-year availability of funding from institutional funding providers can be established by means of funds managed under own responsibility (Selbstbewirtschaftung) or by another budget instrument. These multi-year available funds are shown on the balance sheet as **liabilities to funding providers from institutional funding**. The balance of approved subsidies, own revenues and other income as well as expenditure in the reporting year is shown.

Also shown here are TEUR 14,751 of reimbursement claims of federal states resulting from the MPG's final calculation of fund distribution which in principle are to be paid in the third year following billing; TEUR 8,240 of this amount has a residual term of over one year.

Liabilities to funding providers from project funding essentially contain the funds available for the following year as the balance of third-party funding subsidies received, own revenues and other income, and expenses in the reporting year.

Liabilities due to affiliated companies relate to the Max-Planck-Institut für Eisenforschung GmbH in the framework of funding not yet called off as part of the consortium of applicants in 2021.

Other liabilities contain liabilities towards tax authorities resulting from income tax in the amount of TEUR 12,256 as of the balance sheet date.

The following **statement of liabilities** shows the residual terms of individual liability items (previous-year data in parentheses):

	31.12.2021 TEUR	Residual term		
		up to 1 year TEUR	1 to 5 years TEUR	more than 5 years TEUR
STATEMENT OF LIABILITIES				
Bank borrowings	533 (550)	17 (17)	68 (67)	448 (466)
Trade payables	51,955 (48,042)	51,950 (48,042)	5 (0)	0 (0)
Liabilities to funding providers	291,979 (213,774)	283,739 (207,131)	8,240 (6,643)	0 (0)
Liabilities due to affiliated companies	4,900 (5,039)	4,900 (5,039)	0 (0)	0 (0)
Liabilities due to companies in which an equity interest is held	70 (19)	70 (19)	0 (0)	0 (0)
Other liabilities	22,844 (21,435)	22,308 (20,680)	536 (592)	0 (163)
TOTAL	372,281 (288,859)	362,984 (280,928)	8,849 (7,302)	448 (629)

The liabilities are not secured through rights of lien or similar rights.

3.9 Deferred income and accrued expenses

	31.12.2021 TEUR	31.12.2020 TEUR
Deferred income and accrued expenses	687	1,474

Deferred income and accrued expenses contains revenues received before the balance sheet date which will only be recognized in profit or loss after that date. A total of TEUR 249 of the deferred income and accrued expenses is attributable to the IPP.

4. Explanations to the statement of profit and loss

Subsidies from institutional funding

The subsidies from institutional funding (TEUR 1,969,472, previous year TEUR 1,924,125) are comprised as follows in the reporting year:

	2021 MPG excl. IPP TEUR	2021 IPP TEUR	2021 MPG TEUR	2020 MPG TEUR
SUBSIDIES FROM INSTITUTIONAL FUNDING				
Basic funding	1,834,656	119,629	1,954,285	1,892,901
<i>of which from federal government</i>	1,039,678	108,173	1,147,851	1,114,102
<i>of which from federal states</i>	794,978	11,456	806,434	778,799
Partial special funding	9,150	0	9,150	26,000
<i>of which from federal government</i>	0	0	0	0
<i>of which from federal states</i>	9,150	0	9,150	26,000
Special funding	4,100	0	4,100	3,330
<i>of which from federal government</i>	0	0	0	0
<i>of which from federal states</i>	4,100	0	4,100	3,330
Other partial special funding	1,937	0	1,937	1,894
TOTAL	1,849,843	119,629	1,969,472	1,924,125

The federal government and the federal states provide on a 50:50 basis the financial funding in the **basic funding** of the MPG excluding IPP. For IPP, the ratio of basic funding is 90:10. In accordance with the agreement of the Joint Initiative for Research and Innovation IV, a budget growth of 3% was granted by the funding providers.

Other partial special funding relates to a subsidy from the Netherlands for the MPI for Psycholinguistics, Nijmegen.

Changes in receivables due from funding providers deriving from compensation claims

The change in receivables due from funding providers deriving from compensation claims of TEUR 43,498 (previous year TEUR 63,925) is comprised as follows:

	2021 TEUR	2020 TEUR
MPG excluding IPP	57,681	62,899
IPP	-14,183	1,026

Own revenues and other income

Own revenues and other income (TEUR 274,721 previous year TEUR 255,337) are comprised as follows:

	2021 TEUR	2020 TEUR
OWN REVENUES AND OTHER INCOME		
Income from research and development, and from utilization of research facilities	2,919	3,623
Income from licence and know-how agreements	18,696	20,759
Income from infrastructure services and sales of materials	19,971	25,421
Rental and lease income	12,043	11,539
Income from fixed asset disposals	5,457	5,441
Increase/(-) decrease in work-in-progress	0	0
Other work performed by the enterprise and capitalized	5,901	6,421
Financial income, income from participating interests, interest income	3,251	3,835
Other operating income	206,483	178,298
<i>containing</i>		
Income relating to another accounting period	980	288
Other income	42,493	33,388
Release of multi-year available funds	163,010	144,622

Income from licence and know-how agreements originated from the utilization of the MPG's intangible invention assets by Max-Planck-Innovation GmbH and from the disposal of shares in technology transfer spin-offs. In addition to the income received up to the preparation of the financial statements, the income includes forecast income in the amount of TEUR 9,120 (previous year TEUR 8,639) that is attributable to the financial year but will only be received in the course of the following year.

Income from infrastructure services and sales of materials consists mainly of revenues generated by the MPI for Psychiatry from hospital services.

Rental and lease income results mainly from letting guest apartments and guest rooms. It also contains NÖV income (including the conference venues Schloss Ringberg and Harnack-Haus) in the amount of TEUR 3,405 (previous year TEUR 3,072).

Expenditure arising from the disposal of fixed assets (for subsidy-financed fixed assets) is offset by the same amount of income resulting from the release of the extraordinary item from subsidies for fixed assets, and is shown in **income from fixed asset disposals**.

Of the **other work performed by the enterprise and capitalized** an amount of TEUR 4,517 is attributable to the IPP (previous year: TEUR 4,139).

Financial income, income from participating interests, interest income contains income from securities recognized in NÖV, amounting to TEUR 3,003 (previous year TEUR 3,264).

Income relating to another accounting period includes income from subsequent capitalizations in an amount of TEUR 61.

Other income contains income from the release of provisions amounting to TEUR 14,514 (previous year TEUR 11,240).

Multi-year available funds from institutional funding as well as from project funding in the current year are expensed as a liability to funding providers, and released in the following year as income in the same amount. The **release of multi-year available funds** (from 2020) relates only to MPG excluding IPP, and is comprised as follows:

	TEUR
Release of multi-year available funds	
Basic funding	83,412
Special funding	3,236
Project funding	69,964
Undisbursed funds for operations pursuant to § 26 of the Federal Budget Ordinance (BHO) including MPI for Psychiatry	6,398
TOTAL	163,010

Subsidies from project funds

IPP accounts for 25,274 (previous year TEUR 25,334) of the TEUR 275,985 subsidies from project funds (previous year TEUR 302,797).

Income from the release of extraordinary items (loan repayment)

This item (TEUR 72, previous year TEUR 81) contains the income from the release of the extraordinary item from subsidies for fixed assets arising from redemption payment of family home loans.

Personnel expenses

Personnel expenses (TEUR 1,316,298, previous year TEUR 1,299,959) contain expenses for the support of junior scientists amounting to TEUR 345,206 (previous year TEUR 323,720). Scholarship holders account for TEUR 14,641 (previous year TEUR 16,060).

Social security contributions and expenses for pensions and benefits (TEUR 325,439, previous year TEUR 306,615) includes the balance from the addition to, and consumption of, provisions for pension obligations in an amount of TEUR 55,071 (previous year TEUR 32,077) and for aid obligations in an amount of TEUR 11,060 (previous year TEUR 24,427). Expenses for aid payments were incurred in a total of TEUR 4,901 (previous year TEUR 4,597) and for childcare costs in an amount of TEUR 1,802 (previous year TEUR 1,722).

Costs of materials

Expenses for raw materials, consumables and supplies, and for purchased goods (TEUR 190,089, previous year TEUR 197,515) mainly contain expenses for research materials of TEUR 102,244 (previous year TEUR 108,218) and expenses for power and water supplies amounting to TEUR 85,545 (previous year TEUR 86,851).

Expenses for purchased services of TEUR 10,432 (previous year TEUR 14,552) chiefly represent expenses for awarding external research contracts in the area of third-party funding.

Change in the extraordinary item for current assets

The increase in the extraordinary item for current assets in an amount of TEUR 4,769 is composed of:

- the increase in the extraordinary item recognized on the balance sheet for current assets (TEUR 4,950),
- as well as the changes to shares in spin-offs held for disposal (TEUR 181).

Depreciation and amortization of intangible and tangible fixed assets

Since fixed assets are shown by the gross method, which necessitates showing depreciation and amortization as an expense item in the statement of profit and loss, an amount corresponding to the depreciation and amortization (TEUR 339,512, previous year TEUR 341,539) is released from the extraordinary item of subsidies to fixed assets (TEUR 338,346, previous year TEUR 340,557) without affecting the annual result (for the subsidy-financed fixed assets). The difference corresponds to the depreciation and amortization of the fixed assets not covered by extraordinary items relating to NÖV and MPI for Psychiatry.

No extraordinary write-downs were made on tangible fixed assets (previous year TEUR 1).

Other expenses

Interest and similar expenses (TEUR 14,185, previous year TEUR 15,306) consist almost entirely of interest expenses arising from the reversal of discounts to provisions (TEUR 14,182, previous year TEUR 15,303).

Other operating expenses of TEUR 654,123 (previous year TEUR 599,279) are comprised as follows:

	2021 TEUR	2020 TEUR
Other operating expenses		
Management of land and buildings	170,521	174,773
Libraries	18,981	45,027
Other research expenses	77,511	74,731
of which:		
Travel costs	6,155	7,599
Conferences, advanced training	8,160	7,737
Publications, public relations	7,908	7,747
Other expenses for science and research purposes	55,288	51,648
Business requirements	91,564	89,668
Auditing and advisory costs	22,249	26,086
Further other expenses	29,541	25,984
Expenses from allocation to multi-year available funds	243,756	163,010

The **expenses for allocation to multi-year available funds** are attributable to the MPG excluding IPP and represent the balance of subsidy-financed income and expenses in the statement of profit and loss. They are comprised as follows: They are comprised as follows:

	TEUR
Expenses for allocation to multi-year available funds	
Basic funding	146,416
Special funding	1,525
Project funding	89,123
Undisbursed funds for operations pursuant to § 26 of the Federal Budget Ordinance (BHO) including MPI for Psychiatry	6,692
TOTAL	243,756

The **taxes on income and revenue** amount to 388 TEUR (previous year 0 TEUR).

Transfers and subsidies granted

The MPG is authorized to transfer funding provided to it to various final recipients as a non-repayable subsidy.

Funding was transferred as follows in the reporting year:

	2021 TEUR	2020 TEUR
TRANSFERS AND SUBSIDIES GRANTED		
For institutional funding, MPG excluding IPP		
to institutions within Germany	9,979	10,604
to institutions abroad	22,002	21,234
For project funding, MPG excluding IPP		
in Germany	10,013	9,785
of which from special funding	2,415	300
abroad	2,468	4,934
For the transfer of personnel due to closures/partial closures, MPG excluding IPP	0	0
Transferred IPP subsidies	0	6,566
TOTAL	44,462	53,123
<i>for information purposes: subsidies granted to internal institutions</i>	<i>30,542</i>	<i>28,558</i>

The subsidies granted to internal institutions were consolidated in the annual financial statements.

Expense from addition to the extraordinary item (subsidized investments)

Expenses from addition to the extraordinary item to finance intangible and tangible fixed assets (TEUR 320,180, previous year TEUR 367,105) represent the subsidized investments in these assets. They correlate in their entirety with the additions in the reporting year in accordance with the statement of changes in fixed assets (TEUR 333,068). The difference consists, firstly, of the additions to the NÖV (TEUR 12,949). Secondly, expenses from the addition to the extraordinary item to finance intangible and tangible fixed assets include subsequent capitalizations of the current year at their book value (TEUR 61), which are presented openly in separate columns in the statement of changes in fixed assets.

Expenses from addition to the extraordinary item to finance financial assets and shares in spin-offs (TEUR 183, previous year TEUR 183) result from expenses for the acquisition of shares in spin-offs.

5. Other disclosures

Contingent liabilities and other financial obligations

No risks existed from off-balance sheet transactions as defined by § 285 No. 3 HGB or contingent liabilities pursuant to §251 HGB as of the balance sheet date.

Regarding the Max Planck Digital Library, obligations arise up to the amount of EUR 192.3 million in the period covered by the medium-term budgetary accounting (2022 to 2026) for the MPG-wide basic supply of software and online services as well as literature. The licence contracts required for this purpose are of different durations.

Other financial obligations of around EUR 221.4 million also result from the perspective of the medium-term budgetary accounting of the MPG from the pro rata funding of jointly maintained institutions or joint ventures during scientific collaborations. In particular, this relates the Max Planck Florida Institute for Neuroscience, the Deutsches Klimarechenzentrum GmbH, the Gesellschaft für wissenschaftliche Datenverarbeitung mbH Göttingen, the Institut de Radio Astronomie Millimétrique, Large Binocular Telescope as well as the Square Kilometre Array Observatory.

The MPG appoints its top scientists for life and undertakes as part of the appointment to provide its scientists with funds for their basic scientific equipment. The announced call for these funds will result in possible obligations of around EUR 134.3 million within the timeframe of the medium-term budgetary accounting.

As of 31 December 2021, total construction costs budgeted but not yet disbursed amount to around EUR 694.4 million for major construction projects already commenced by Institutes and facilities.

Order obligations aside from construction projects total around EUR 71.9 million as of 31 December 2021.

Employees

The MPG employed an average of 19,803 staff during the financial year:

	Number 2021	Number 2020
Scientists	6,582	6,675
Doctoral students with funding contracts	3,293	3,247
Non-scientific staff	8,415	8,476
Student and graduate assistants	1,513	1,619
EMPLOYEES (excluding trainees and interns)	19,803	20,017
<i>for information purposes: Scholarship holders</i>	<i>487</i>	<i>518</i>

Participations

The MPG holds shares in other companies or major international projects in order to exploit synergy effects for scientific assignments to the best possible long-term advantage.

As of 31 December 2021, the following shareholdings existed:

Name	Registered seat	Purpose	Share in the capital %	Book value as of 31.12.2021 EUR
SHARES IN AFFILIATED COMPANIES				
Max-Planck-Innovation GmbH	Munich	The company manages and exploits intangible invention assets owned by the Max Planck Society.	100	500,000
Minerva Stiftung Gesellschaft für die Forschung mbH	Munich	The purpose of the (non-profit) company is to fund science and research, on the one hand by providing financial support for research projects at home and abroad, and on the other by operating funding programmes, principally in Israel.	100	26,000
Max-Planck-Stiftung für Internationalen Frieden und Rechtsstaatlichkeit gemeinnützige GmbH	Heidelberg	The purpose of the company is the advancement of science and research, the international ethos of tolerance and the concept of international understanding, development cooperation, public and professional education as well as democracy as a political system.	100	25,000
Deutsches Klimarechenzentrum GmbH	Hamburg	The object and purpose of the (non-profit) company is the promotion of basic research and applied research in climatology and the disciplines immediately related to climatology. The purpose is achieved in particular through the expansion and operation of a climate computing centre.	54.5	31,200
Max-Planck-Institut für Eisenforschung Gesellschaft mit beschränkter Haftung	Düsseldorf	This (non-profit) company conducts basic research in the field of iron, steel and related materials.	100	26,000

Name	Registered seat	Purpose	Share in the capital %	Book value as of 31.12.2021 EUR
PARTICIPATIONS				
Gesellschaft für wissenschaftliche Datenverarbeitung mbH Göttingen	Göttingen	This (non-profit) company promotes science and research. It fulfils the function of a computing and competence centre for the MPG and a university computing centre for the University of Göttingen.	50	26,000
Max Planck Graduate Center mit der Johannes Gutenberg-Universität Mainz GmbH	Mainz	The object of the (non-profit) company is the advancement of science and research, in particular by means of interdisciplinary teaching and doctoral programmes for junior scientists.	50	12,500
UltraFast Innovations GmbH	Garching	The object of the company is to develop and produce special mirror optics and filters with tailor-made properties for laser applications, as well as laser systems and measurement equipment in which these optics are used.	50	12,500
Institut de Radio Astronomie Millimétrique	Grenoble/ France	The object is the joint operation of two observation stations on Pico Veleta (30-metre telescope) in Spain and on the Plateau de Bure (NOEMA observatory with twelve 15-metre telescopes) in France as well as a science laboratory in Grenoble, France.	47	716.75
EuResist Network GEIE	Rom/Italy	European Economic Interest Grouping, founded as part of the 7th EU research framework programme for the „CHAIN – Collaborative HIV and Anti-HIV Drug Resistance Network“ project.	20	3,100.22
Wissenschaft im Dialog gGmbH	Berlin	The object of the company is to promote dialogue between science and society with special regard to the latest public forms of communication, to promote understanding between science, research and the public, information on the methods and processes of scientific research as well as to emphasize the mutual interactions and dependencies of science, business and society.	8.33	5,000
Schloss Dagstuhl – Leibniz Zentrum für Informatik Gesellschaft mit beschränkter Haftung	Wadern	As an international meeting point and research centre for computer science, the task of this (non-profit) company is to conduct scientific computer science conferences.	7.7	5,200
Cherenkov Telescope Array Observatory gemeinnützige GmbH	Heidelberg	The company is responsible for: – developing the planning and preparing the realization of the CTAO Facility as well as the development of the founding accord for the construction and Operation of the CTAO Facility – selecting and equipping the telescope locations – planning and development as well as construction and operation of prototype telescopes and related instruments and infrastructure for test purposes – preparation of programmes for scientific research conducted in the CTAO Facility.	5	1,250
FIZ Karlsruhe – Leibniz Institut für Informationsinfrastruktur GmbH	Eggenstein-Leopoldshafen	The task of this (non-profit) company is to provide science and research with scientific information, develop corresponding products and services in the field of scientific information infrastructure and to make them publicly accessible.	3.26	1,560
LSI Pre-Seed-Fonds GmbH	Bonn	LSI PSF GmbH operates together with Life Science Inkubator GmbH & Co. KG (management company Life Science Inkubator GmbH is a wholly-owned subsidiary of Max-Planck Innovation GmbH) an incubator for researchers from German universities and research facilities interested in founding their own company.	1.5	220,000

Name	Registered seat	Purpose	Share in the capital %	Book value as of 31.12.2021 EUR
Futurium gGmbH (formerly: Haus der Zukunft gGmbH)	Berlin	The company's purpose is to operate the Futurium as a location for presentations and dialog for science, research and development. Exhibitions and events are to make future-oriented scientific and technical developments of national and international significance visible, and present them for discussion.	1	250

No details are given of these companies' equity or their results in the last financial year due to their subordinate significance in accordance with § 286 para. 3 sentence 1 No. 1 HGB.

The MPG refrains from preparing consolidated financial statements in the meaning of No. 14 (1) of the Management Principles for the MPG (BewGr-MPG), as the participations reported under the balance sheet item "shares in affiliated companies" are of subordinate significance, both individually as well as together, for the net assets, financial position and results of operations of the MPG.

MPG Bodies in their tasks

The MPG Statutes specify the following bodies:

- the President,
- the Executive Committee,
- the Senate,
- the General Meeting,
- the Scientific Council and its Sections

The **President** represents the Max Planck Society, drafts the outlines of its science policy, and works to ensure trustful collaboration within the Max Planck Society. The President chairs the Senate, Executive Committee and General Meeting. In cases that cannot be deferred, the President may make decisions falling within these bodies' competency.

The **Executive Committee** advises the President and prepares resolutions for the Senate and the General Meeting. It prepares the overall budget and submits it to the Senate for adoption. It also prepares the annual report as well as the annual accounts for adoption by the Senate. Furthermore, through the President, it exercises a supervisory role over the Administrative Headquarters and possesses the decision-making power in all of the Society's matters that are not allocated to another body and that extend above and beyond current transactions to be managed by the Administrative Headquarters. Together with the Secretary General (the Secretary Generals), it forms the Management Board in the meaning of the law.

The **Senate** is an important decision-making body of the Max Planck Society. The Senate elects the President and other members of the Executive Committee and decides on the appointment of the Secretary General. It decides on the foundation and closure of Institutes and Departments, the appointment of Scientific Members and the by-laws of the Institutes. The Senate decides on the involvement of the Max Planck Society in other institutions and approves the overall budget; it also approves the annual report and presents it to the General Meeting. It adopts the annual accounts and decides on the admission of Supporting Members. The Senate can also pass resolutions on all matters of the Max Planck Society that the Statutes do not reserve for the General Meeting. The voting-entitled members of the Senate include both Elected Senators and Ex officio Members. The Senate's composition reflects the aim to draw on experience from all important areas of public life in important decisions. For this reason, the Elected Senators – of whom there are a minimum of twelve and a maximum of 32 – include not only outstanding MPG scientists but also high-ranking representatives of the federal government and the federal states, important personalities from business enterprises and scientific organizations as well as other socially relevant groups.

The Senate is supported by three Senate Committees:

- The **Senate Committee for Research Planning** advises on questions of research policy and research planning.
- The **Audit Committee** reviews the lawfulness of budget implementation and the correctness of the Society's accounting, as well as the effectiveness of its risk and compliance management. It makes proposals to the General Meeting regarding the appointment of external auditors, determines the criteria and scope of the audit engagement and receives the external auditors' reports. It receives the annual report of the Internal Auditing Department and is authorized to prompt further audits.
- The task of the **Employment Committee** is to decide upon the reward of and upon the approval of ancillary activities undertaken by the President and upon the reward of and upon the approval of function-related ancillary activities undertaken by the other members of the Executive Committee. The Employment Committee is further tasked with deciding upon the reward of former Presidents in return for the performance of tasks for the Society.

The **General Meeting** (the meeting of its members) is the uppermost association body of the Max Planck Society. It decides on amendments to the Society's Statutes, elects the Senate members, receives the annual report, audits and approves the annual accounts, and grants approbation. The Society's members include its Scientific Members, Supporting Members, Ex officio Members, and Honorary Members.

The **Scientific Council** consists of Scientific Members and the heads of the Institutes and of research facilities equivalent to Institutes. It also comprises scientific staff elected by the Institutes to the Sections. The Emeritus Scientific Members and the External Scientific Members of the Institute may attend meetings as guests in an advisory capacity. The Scientific Council is divided into three Sections. The Sections' task is to discuss the Institutes' joint matters and prepare the Senate's scientific decisions through specialist recommendations.

Staff of the MPG governing bodies²**PRESIDENT**

Martin Stratmann, Prof. Dr., München, Wissenschaftliches Mitglied des Max-Planck-Instituts für Eisenforschung GmbH, Düsseldorf

EXECUTIVE COMMITTEE

PRESIDENT – CHAIRPERSON

Martin Stratmann, Prof. Dr., München, Wissenschaftliches Mitglied des Max-Planck-Instituts für Eisenforschung GmbH, Düsseldorf

VICE PRESIDENTS

Asifa Akhtar, Dr., Wissenschaftliches Mitglied und Direktorin am Max-Planck-Institut für Immunbiologie und Epigenetik, Freiburg

Andreas Barner, Prof. Dr. Dr., Mitglied des Gesellschafterausschusses der C. H. Boehringer Sohn AG & Co. KG, Ingelheim am Rhein, und Präsident des Stifterverbandes für die Deutsche Wissenschaft e.V., Essen

Klaus Blaum, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kernphysik, Heidelberg

Ulman Lindenberger, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Bildungsforschung, Berlin

TREASURER

Ralf P. Thomas, Prof. Dr., Mitglied des Vorstands und Chief Financial Officer der Siemens AG, München

OTHER MEMBERS

Nikolaus von Bomhard, Dr., Vorsitzender des Aufsichtsrats der Münchener Rückversicherungs-Gesellschaft, München

Nicola Leibinger-Kammüller, Dr., Vorsitzende der Geschäftsführung der TRUMPF GmbH & Co. KG, Ditzingen

MANAGEMENT BOARD

Together with the Secretary General, **Rüdiger Willems** (until 31 May 2022), and the Secretary General, **Dr. Simone Schwanitz** (since 1 February 2022), Munich, the Executive Committee forms the Management Board in the sense of the law.

SENATE

CHAIRPERSON

Martin Stratmann, Prof. Dr., Präsident der Max-Planck-Gesellschaft, München, Wissenschaftliches Mitglied des Max-Planck-Instituts für Eisenforschung GmbH, Düsseldorf

ELECTED SENATORS

Asifa Akhtar, Dr., Vizepräsidentin der Max-Planck-Gesellschaft, Wissenschaftliches Mitglied und Direktorin am Max-Planck-Institut für Immunbiologie und Epigenetik, Freiburg

Frank Appel, Dr., Vorstandsvorsitzender der Deutschen Post DHL Group, Bonn

Simone Bagel-Trah, Dr., Vorsitzende des Aufsichtsrats und des Gesellschafterausschusses der Henkel AG & Co. KGaA, Düsseldorf

Andreas Barner³, Prof. Dr. Dr., Vizepräsident der Max-Planck-Gesellschaft, Mitglied des Gesellschafterausschusses der C. H. Boehringer Sohn AG & Co. KG, Ingelheim am Rhein, und Präsident des Stifterverbandes für die Deutsche Wissenschaft e.V., Essen

Theresia Bauer⁴, MdL, Ministerin für Wissenschaft, Forschung und Kunst des Landes Baden-Württemberg, Stuttgart

Heinrich Bedford-Strohm, Prof. Dr., Landesbischof der Evangelisch-Lutherischen Kirche in Bayern, München

Ulrike Beisiegel, Prof. Dr. Dr. h.c., ehem. Präsidentin der Universität Göttingen, Hamburg

Klaus Blaum, Prof. Dr., Vizepräsident der Max-Planck-Gesellschaft, Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kernphysik, Heidelberg

²The dates in brackets show the date of leaving (until/bis) or joining (since/seit) the respective governing body.

³Prof. Barner ist zugleich ständiger Gast des Senats der Max-Planck-Gesellschaft als Präsident des Stifterverbandes für die Deutsche Wissenschaft e.V.

⁴Frau Bauer ist zugleich ständiger Gast des Senats der Max-Planck-Gesellschaft als Vertreterin der Länder.

Nikolaus von Bomhard, Dr., Mitglied des Verwaltungsrats der Max-Planck-Gesellschaft, Vorsitzender des Aufsichtsrats der Münchener Rückversicherungs-Gesellschaft, München

Martin Bruder Müller, Dr., Vorstandsvorsitzender der BASF SE, Ludwigshafen

Malu Dreyer, Ministerpräsidentin des Landes Rheinland-Pfalz, Mainz

Joachim Gauck, Bundespräsident a.D. der Bundesrepublik Deutschland, Berlin

Sibylle Günter, Prof. Dr., Wissenschaftliches Mitglied und Wissenschaftliche Direktorin des Max-Planck-Instituts für Plasma-physik, Garching

Franz-Ulrich Hartl, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Biochemie, Martinsried

Edith Heard, Prof. Ph.D., FRS, Director General des European Molecular Biology Laboratory, Heidelberg

Stefan W. Hell, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für biophysikalische Chemie (Karl-Friedrich-Bonhoeffer-Institut), Göttingen, und Direktor am Max-Planck-Institut für medizinische Forschung, Heidelberg

Wolfgang A. Herrmann, Prof. Dr. Dr. h. c. mult., ehem. Präsident der Technischen Universität München, Garching

Berthold Huber, ehem. Erster Vorsitzender der IG Metall, Frankfurt/Main

Jürgen Kaube, Mitherausgeber der Frankfurter Allgemeinen Zeitung, Frankfurt/Main

Michael Kretschmer, Ministerpräsident des Freistaates Sachsen, Dresden

Sabine Kunst, Prof. Dr.-Ing. Dr., bis 31.12.2021 Präsidentin der Humboldt-Universität zu Berlin

Nicola Leibinger-Kammüller, Dr., Mitglied des Verwaltungsrats der Max-Planck-Gesellschaft, Vorsitzende der Geschäftsführung der TRUMPF GmbH & Co. KG, Ditzingen

Ulman Lindenberger, Prof. Dr., Vizepräsident der Max-Planck-Gesellschaft, Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Bildungsforschung, Berlin

Anton Losinger, Dr. Dr., Weihbischof des Bistums Augsburg, Augsburg

Mai Thi Nguyen-Kim, Dr., Wissenschaftsjournalistin, Rödermark

Norbert Reithofer, Dr.-Ing. Dr.-Ing. E. h., Vorsitzender des Aufsichtsrats der Bayerischen Motoren Werke Aktiengesellschaft, München

Peter Seeberger, Prof. Dr., Wissenschaftliches Mitglied und Direktor des Max-Planck-Instituts für Kolloid- und Grenzflächenforschung, Potsdam

Ralf P. Thomas, Prof. Dr., Schatzmeister der Max-Planck-Gesellschaft, Mitglied des Vorstands und Chief Financial Officer der Siemens AG, München

Andreas Voßkuhle, Prof. Dr., Präsident a.D. des Bundesverfassungsgerichts, Freiburg

Daniel Zajfman, Prof. Dr., Auswärtiges Wissenschaftliches Mitglied des Max-Planck-Instituts für Kernphysik, Heidelberg, Chair of the Academic Board of Particle Physics and Astrophysics, Weizmann Institute of Science, Rehovot, Israel

Reinhard Zimmermann, Prof. Dr. Dr. h. c. mult., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für ausländisches und internationales Privatrecht, Hamburg

Maciej Zyllicz, Prof. Dr. Dr. h. c., President and Executive Director of the Foundation for Polish Science, Warschau, Polen

EX OFFICIO MEMBERS

Hubert Aiwanger, MdL, Bayerischer Staatsminister für Wirtschaft, Landesentwicklung und Energie, München, als Vertreter der Länder

Ulrich Becker, Prof. Dr. LL. M. (EHI), Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Sozialrecht und Sozialpolitik, München, als Vorsitzender der Geistes-, Sozial- und Humanwissenschaftlichen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

Gabriele Bixel, Priv.-Doz. Dr., wissenschaftliche Mitarbeiterin am Max-Planck-Institut für molekulare Biomedizin, Münster, als Vertreterin der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Biologisch-Medizinischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

Markus Burtscheidt, als Vorsitzender des Gesamtbetriebsrates der Max-Planck-Gesellschaft, Köln

Peter Druschel, Prof. Ph.D., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Softwaresysteme, Saarbrücken, als Vorsitzender der Chemisch-Physikalisch-Technischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

Werner Gatzert, Staatssekretär im Bundesministerium der Finanzen, Berlin, als Vertreter des Bundes

Hana Gründler, Dr., Permanent Senior Research Scholar am Kunsthistorischen Institut in Florenz – Max-Planck-Institut, Florenz, Italien, als Vertreterin der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Geistes-, Sozial- und Humanwissenschaftlichen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

Reinhold Hilbers, Finanzminister des Landes Niedersachsen, Hannover, als Vertreter der Länder

Anja Karliczek, MdB, Bundesministerin für Bildung und Forschung, Berlin, als Vertreterin des Bundes (bis 06.12.2021)

Bernhard Keimer, Honorarprof. Ph.D., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Festkörperforschung, Stuttgart, als Vorsitzender des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

Eduardo Ros Ibarra, Prof. Dr., wissenschaftlicher Mitarbeiter am Max-Planck-Institut für Radioastronomie, Bonn, als Vertreter der wissenschaftlichen Mitarbeiterinnen und Mitarbeiter der Chemisch-Physikalisch-Technischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft

Manja Schüle, Dr., Ministerin für Wissenschaft, Forschung und Kultur des Landes Brandenburg, Potsdam, als Vertreterin der Länder

Martin Vingron, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für molekulare Genetik, Berlin, als Vorsitzender der Biologisch-Medizinischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (seit 25.06.2021)

Rüdiger Willems, als Generalsekretär der Max-Planck-Gesellschaft, München

Lothar Willmitzer, Prof. Dr. Dr. h.c., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für molekulare Pflanzenphysiologie, Potsdam, als Kommissarischer Vorsitzender der Biologisch-Medizinischen Sektion des Wissenschaftlichen Rates der Max-Planck-Gesellschaft (bis 24.06.2021)

SENATORS WITHOUT VOTING RIGHTS

HONORARY MEMBERS

Peter Gruss, Prof. Dr., Martinsried, Präsident der Max-Planck-Gesellschaft von 2002 bis 2014, Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für biophysikalische Chemie (Karl-Friedrich-Bonhoeffer-Institut), Präsident des Okinawa Institute of Science and Technology Graduate University

Reinhard Pöllath, Prof. Dr., Rechtsanwalt, Kanzlei P+P Pöllath + Partners Rechtsanwälte und Steuerberater mbB, München

HONORARY SENATORS

Ernst-Joachim Mestmäcker, Prof. Dr. Dr. h.c., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für ausländisches und internationales Privatrecht, Hamburg

Christiane Nüsslein-Volhard, Prof. Dr., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für Entwicklungsbiologie, Tübingen

PERMANENT GUESTS OF THE SENATE

Peter-André Alt, Prof. Dr., als Präsident der Hochschulrektorenkonferenz, Bonn

Andreas Barner⁵, Prof. Dr. Dr., Vizepräsident der Max-Planck-Gesellschaft, Mitglied des Gesellschafterausschusses der C. H. Boehringer Sohn AG & Co. KG, Ingelheim am Rhein, als Präsident des Stifterverbandes für die Deutsche Wissenschaft e.V., Essen

Theresia Bauer⁶, MdL, Ministerin für Wissenschaft, Forschung und Kunst des Landes Baden-Württemberg, Stuttgart, als Vertreterin der Länder

Katja Becker, Prof. Dr., als Präsidentin der Deutschen Forschungsgemeinschaft, Bonn

Gerald Haug, Prof. (ETHZ) Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Chemie (Otto-Hahn-Institut), Mainz, Deutsche Akademie der Naturforscher Leopoldina, Halle (Saale), als Präsident der Nationalen Akademie der Wissenschaften

Matthias Kleiner, Prof. Dr.-Ing., als Präsident der Leibniz-Gemeinschaft, Berlin

Wolf-Dieter Lukas, Prof. Dr., Staatssekretär im Bundesministerium für Bildung und Forschung, Bonn, als Vertreter des Bundes

⁵Prof. Barner ist zugleich Wahlsenator der Max-Planck-Gesellschaft.

⁶Frau Bauer ist zugleich Wahlsenatorin der Max-Planck-Gesellschaft.

Reimund Neugebauer, Prof. Dr.-Ing., als Präsident der Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., München

Wolfgang Tiefensee, Thüringer Minister für Wirtschaft, Wissenschaft und Digitale Gesellschaft, Erfurt, als Vertreter der Länder

Dorothea Wagner, Prof. Dr., als Vorsitzende des Wissenschaftsrates, Köln

Otmar D. Wiestler, Prof. Dr. Dr. h. c., als Präsident der Hermann von Helmholtz-Gemeinschaft Deutscher Forschungszentren e.V., Berlin

SENATE COMMITTEES

SENATE COMMITTEE FOR RESEARCH PLANNING
The Senate Committee for Research Planning has been dormant since 2016. No meetings have taken place in the meantime.

AUDIT COMMITTEE OF THE SENATE

Clemens Börsig, Prof. Dr. rer. pol., ehem. Aufsichtsratsvorsitzender der Deutschen Bank, Frankfurt/Main, als Förderndes Mitglied der Max-Planck-Gesellschaft (bis 19.11.2021)

Berthold Huber, ehem. Erster Vorsitzender der IG Metall, Frankfurt/Main, als Wahlsenator der Max-Planck-Gesellschaft

Henning Kagermann, Prof. Dr. Dr.-Ing. E. h., Vorsitzender des Kuratoriums der acatech – Deutsche Akademie der Technikwissenschaften, München, als Förderndes Mitglied der Max-Planck-Gesellschaft (seit 19.11.2021)

Sabine Kunst, Prof. Dr.-Ing. Dr., bis 31.12.2021 Präsidentin der Humboldt-Universität zu Berlin, als Wahlsenatorin der Max-Planck-Gesellschaft

EMPLOYMENT COMMITTEE OF THE SENATE

Heinrich Bedford-Strohm, Prof. Dr., Landesbischof der Evangelisch-Lutherischen Kirche in Bayern, München, als Wahlsenator der Max-Planck-Gesellschaft

Reinhard Pöllath, Prof. Dr., Ehrenmitglied des Senats der Max-Planck-Gesellschaft, Rechtsanwalt, Kanzlei P+P Pöllath + Partners Rechtsanwälte und Steuerberater mbB, München, als Förderndes Mitglied der Max-Planck-Gesellschaft

Andreas Voßkuhle, Prof. Dr., Präsident a.D. des Bundesverfassungsgerichts, Freiburg, als Wahlsenator der Max-Planck-Gesellschaft

GENERAL MEETING

CHAIRPERSON

Martin Stratmann, Prof. Dr., Präsident der Max-Planck-Gesellschaft, München, Wissenschaftliches Mitglied des Max-Planck-Instituts für Eisenforschung GmbH, Düsseldorf

MEMBERS

The General Meeting consists of the Members of the Max-Planck-Gesellschaft. These are: Supporting Members, Scientific Members, Ex officio Members and Honorary Members.

SCIENTIFIC COUNCIL

CHAIRPERSON

Bernhard Keimer, Honorarprof. Ph.D., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Festkörperforschung, Stuttgart

VICE CHAIRPERSON

Mikko Myrskylä, Prof. Ph.D., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für demografische Forschung, Rostock

BIOLOGY & MEDICINE SECTION

CHAIRPERSON

Martin Vingron, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für molekulare Genetik, Berlin (seit 25.06.2021)

Lothar Willmitzer, Prof. Dr. Dr. h. c., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für molekulare Pflanzenphysiologie, Potsdam, Kommissarischer Vorsitzender der Biologisch-Medizinischen Sektion (bis 24.06.2021)

VICE CHAIRPERSON

Lothar Willmitzer, Prof. Dr. Dr. h. c., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für molekulare Pflanzenphysiologie, Potsdam (bis 18.02.2021 und seit 25.06.2021)

Martin Vingron, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für molekulare Genetik, Berlin (seit 19.02.2021 bis 24.06.2021)

MEDIATORS

Ralf Conrad, Prof. Dr., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für terrestrische Mikrobiologie, Marburg (bis 24.06.2021)

Regine Kahmann, Prof. Dr., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für terrestrische Mikrobiologie, Marburg (seit 25.06.2021)

Franz-Ulrich Hartl, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Biochemie, Martinsried

Camila Caldana, Dr., wissenschaftliche Mitarbeiterin des Max-Planck-Instituts für molekulare Pflanzenphysiologie, Potsdam (bis 24.06.2021)

Daniel Piechowski, Dr., wissenschaftlicher Mitarbeiter des Max-Planck-Instituts für Verhaltensbiologie, Radolfzell (seit 25.06.2021)

CHEMISTRY, PHYSICS & TECHNOLOGY SECTION

CHAIRPERSON

Peter Druschel, Prof. Ph.D., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Softwaresysteme, Saarbrücken

VICE CHAIRPERSON

Michael Kramer, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Radioastronomie, Bonn (seit 25.06.2021)

Peter Fratzl, Prof. Dr. Dr. h. c., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kolloid- und Grenzflächenforschung, Potsdam (bis 24.06.2021)

MEDIATORS

Gerhard Dehm, Univ.-Prof. Dipl.-Ing. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Eisenforschung GmbH, Düsseldorf

Gerd Leuchs, Prof. Dr., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für die Physik des Lichts, Erlangen

Johannes Wicht, Dr., wissenschaftlicher Mitarbeiter des Max-Planck-Instituts für Sonnensystemforschung, Göttingen

HUMAN SCIENCES SECTION

CHAIRPERSON

Ulrich Becker, Prof. Dr. LL. M. (EHI), Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Sozialrecht und Sozialpolitik, München

VICE CHAIRPERSON

Arno Villringer, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Kognitions- und Neurowissenschaften, Leipzig (seit 25.06.2021)

Jürgen Renn, Prof. Dr., Wissenschaftliches Mitglied und Direktor am Max-Planck-Institut für Wissenschaftsgeschichte, Berlin (bis 24.06.2021)

MEDIATORS

Wolfgang Klein, Prof. Dr., Emeritiertes Wissenschaftliches Mitglied des Max-Planck-Instituts für Psycholinguistik, Nijmegen, Niederlande

Antje-Susanne Meyer, Prof. Dr., Wissenschaftliches Mitglied und Direktorin am Max-Planck-Institut für Psycholinguistik, Nijmegen, Niederlande

Johannes Röll, Dr., wissenschaftlicher Mitarbeiter der Bibliotheca Hertziana – Max-Planck-Institut für Kunstgeschichte, Rom, Italien

Additional information

Total emoluments for the President, Vice President and Secretary General for their work on the Management Board and Executive Committee amounted to TEUR 584 for the calendar year 2021. Total emoluments for former members of the Management Board or Executive Committee (Civil Servant-type pensions and benefits for surviving dependants) amounted to TEUR 316. Provisions amounting to TEUR 3,297 exist for pension obligations to former members of the Management Board or Executive Committee. The Treasurer and other members of the Executive Committee did not receive any emoluments for their work on the Management Board and Executive Committee. Members of the Senate also received no emoluments for their work in the Senate.

The total fee for the auditor in the 2021 financial year amounted to TEUR 223. This related exclusively to work performed for the auditing of the annual financial statements.

No transactions of any material significance to the MPG were realized on non-standard terms with affiliated companies or persons.

The MPG holds all shares in the special securities assets fund DeAM-Fonds PMF 1 ISIN DE0008498080. The fund consists of two segments, "DBA" and "Others". Around 73% of the securities investments were actively managed in the DBA segment by a manager. The other securities investments (27%) in the Others segment are distributed across institutional funds in a diversified port-folio in accordance with the advisory support of an Investment Advisory Board. All securities assets are allocated in accordance with defined investment guidelines paying special attention to the criteria of risk, return, liquidity and sustainability of investments. As of 31 December 2021, the market value stood at EUR 180.17 million. The difference between this and the book value (EUR 136.52 million) amounted to EUR 43.65 million. No write-downs were required. The income generated in the 2021 reporting year from the special fund amounted to EUR 2.87 million. No restrictions of any legal or actual kind exist with regard to the redemption of shares.

Events of particular significance after the end of the financial year

On 1 January 2022, the caesar research center was integrated into the MPG e.V. and has since been run as a legally dependent Institute. The assets of the former foundation were transferred to MPG e.V. for the intended purpose of financing the institute, which significantly increased the financial assets in particular.

In response to the Russian war of aggression in Ukraine, which was launched on 24 February 2022, NATO and the EU have tightened foreign trade regulations as well as sanctions and embargo provisions. Research cooperations with state institutions and business enterprises in Russia and Belarus have been frozen until further notice and are being reviewed in particular with regard to export control law. This affects, among others, large collaboration projects with Russia such as FAIR, Icarus, eRosita, ZOTTO and ExoMars, in which Max Planck Institutes are also involved. In addition, further burdens and uncertainties are caused by the rapidly rising energy costs, supply difficulties and the resulting price increases, as well as by developments on the capital markets.

Berlin, 29 April 2022

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin
– The Executive Committee –

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin

Annex to the notes to the financial statements

STATEMENT OF CHANGES IN FIXED ASSETS AS OF 31 DECEMBER 2021

	COSTS OF PURCHASING OR MANUFACTURING					
	Balance on 01.01.2021 EUR	Addition 2021 EUR	Subsequent capitalization 2021 EUR	Disposal 2021 EUR	Rebooking 2021 EUR	Balance on 31.12.2021 EUR
I. INTANGIBLE ASSETS						
1. Purchased concessions, industrial property rights and similar rights and assets, as well as licences to such rights and assets	78,001,147.49	7,930,495.24	12,611.53	-5,028,379.44	2,159,703.50	83,075,578.32
2. Prepayments made	2,602,072.81	1,066,998.45	0.00	0.00	-2,160,903.50	1,508,167.76
	80,603,220.30	8,997,493.69	12,611.53	-5,028,379.44	-1,200.00	84,583,746.08
II. TANGIBLE FIXED ASSETS						
1. Land, rights equivalent to land, and buildings including buildings on third-party land	2,594,863,348.53	27,783,177.76	0.00	-5,657,208.10	25,011,918.57	2,642,001,236.76
2. Technical plant and machinery	3,128,170,822.24	111,112,605.64	182,216.28	-110,088,727.93	50,734,357.72	3,180,111,273.95
3. Other plant, operating and office equipment	1,102,714,247.12	56,183,106.41	112,124.85	-41,365,509.07	6,016,713.43	1,123,660,682.74
4. Prepayments made and plant under construction	312,453,053.38	128,991,547.36	0.00	-1,293,966.11	-81,761,789.72	358,388,844.91
	7,138,201,471.27	324,070,437.17	294,341.13	-158,405,411.21	1,200.00	7,304,162,038.36
III. FINANCIAL ASSETS						
1. Shares in affiliated companies	608,200.00	0.00	0.00	0.00	0.00	608,200.00
2. Participations	288,076.97	0.00	0.00	0.00	0.00	288,076.97
3. Investment securities	137,453,517.19	15,849,999.20	0.00	-1,777,201.66	0.00	151,526,314.73
4. Other loans and shares	2,469,695.08	409,900.00	0.00	-246,983.41	0.00	2,632,611.67
	140,819,489.24	16,259,899.20	0.00	-2,024,185.07	0.00	155,055,203.37
TOTAL	7,359,624,180.81	349,327,830.06	306,952.66	-165,457,975.72	0.00	7,543,800,987.81

DEPRECIATION AND AMORTIZATION							BOOK VALUES		
Accumulated 01.01.2021 EUR	Financial year 2021 EUR	to subsequent capitalization 2021 EUR	to disposal 2021 EUR	to rebooking 2021 EUR	Write-up 2021 EUR	Accumulated 31.12.2021 EUR	Balance on 31.12.2021 EUR	Balance on 01.01.2021 EUR	
-68,721,201.97	-7,710,359.32	-5,898.80	5,020,160.44	0.00	0.00	-71,417,299.65	11,658,278.67	9,279,945.52	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,508,167.76	2,602,072.81	
-68,721,201.97	-7,710,359.32	-5,898.80	5,020,160.44	0.00	0.00	-71,417,299.65	13,166,446.43	11,882,018.33	
-1,399,716,720.05	-67,569,476.47	0.00	2,563,913.46	5,564.65	0.00	-1,464,716,718.41	1,177,284,518.35	1,195,146,628.48	
-2,632,245,099.54	-182,676,171.40	-144,773.75	108,511,678.66	310,453.02	16,757.44	-2,706,227,155.57	473,884,118.38	495,925,722.70	
-919,289,164.56	-81,555,696.49	-94,931.76	40,728,101.26	-316,017.67	29,369.36	-960,498,339.86	163,162,342.88	183,425,082.56	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	358,388,844.91	312,453,053.38	
-4,951,250,984.15	-331,801,344.36	-239,705.51	151,803,693.38	0.00	46,126.80	-5,131,442,213.84	2,172,719,824.52	2,186,950,487.12	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	608,200.00	608,200.00	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	288,076.97	288,076.97	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	151,526,314.73	137,453,517.19	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	2,632,611.67	2,469,695.08	
0.00	0.00	0.00	0.00	0.00	0.00	0.00	155,055,203.37	140,819,489.24	
-5,019,972,186.12	-339,511,703.68	-245,604.31	156,823,853.82	0.00	46,126.80	-5,202,859,513.49	2,340,941,474.32	2,339,651,994.69	

INDEPENDENT AUDITORS REPORT

To the Max Planck Society for the Advancement of Science (Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.), Berlin

Audit opinions

We have audited the annual financial statements, of the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin, comprising the balance sheet as at 31 December 2021, the statement of profit and loss for the financial year from 1 January to 31 December 2021, and the notes to the annual financial statements, including the presentation of the accounting policies. In addition, we have audited the management report of the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin, for the financial year from 1 January to 31 December 2021.

In our opinion, on the basis of the knowledge obtained in the audit,

- the enclosed annual financial statements comply in all significant respects with the German commercial law regulations applicable to corporations and gives a true and fair view pursuant to the German principles of proper accounting of the net assets and financial position of the association as of 31 December 2021 as well as of the results of operations for the financial year from 1 January to 31 December 2021, and
- the enclosed management report as a whole provides a suitable view of the association's position. In all significant respects, the management report is consistent with the annual financial statements, complies with German statutory regulations and suitably presents the opportunities and risks of future development.

Pursuant to §322 para. 3 sentence 1 German Commercial Code (HGB), we declare that our audit has not led to reservations against the correctness of the annual financial statements and of the management report.

Basis for the audit opinions

We conducted our audit of the annual financial statements and of the management report in accordance with § 317 HGB and in compliance with German generally accepted standards for the audit of financial statements promulgated by the Institute of Public Auditors in Germany (IDW). Our responsibility under these regulations and principles are further described in "The auditor's responsibility for the audit of the annual financial statements and the management report" section of our auditor's report. We are independent of the association in accordance with the German commercial law and professional law regulations and we have fulfilled our other German professional obligations in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions on the annual financial statements and on the management report.

Responsibility of the Executive Committee and of the Audit Committee for the annual financial statements and the management report

The Executive Committee is responsible for the preparation of the annual financial statements that comply, in all significant respects, with the German commercial law regulations applicable to corporations, and for the annual financial statements that give a true and fair view of the net assets, financial position and results of operations of the association in accordance with

German principles of proper accounting. Furthermore, the Executive Committee is responsible for such internal controls as they, in accordance with German principles of proper accounting, have determined necessary to permit the preparation of annual financial statements that are free from material misstatements, whether intentional or unintentional.

In preparing the annual financial statements, the Executive Committee is responsible for assessing the association's ability to continue as a going concern. Moreover, the Executive Committee has the responsibility for disclosing, as applicable, matters related to going concern. In addition, it is responsible for accounting based on the going concern accounting principle, unless actual or legal circumstances preclude this.

The Executive Committee is also responsible for the preparation of the management report, that as a whole provides a suitable view of the association's position and which is consistent with the annual financial statements in all significant respects, complies with German statutory regulations and suitably presenting the opportunities and risks of future development. The Executive Committee is furthermore responsible for the provisions and measures (systems) that it deems necessary to enable the preparation of a management report in accordance with the applicable German statutory regulations and to be able to provide sufficient appropriate evidence for the statements contained in the management report.

The Audit Committee is responsible for monitoring the association's accounting process of preparing the annual financial statements and the management report.

The auditor's responsibility for the audit of the annual financial statements and the management report

It is our objective to obtain sufficient certainty whether the annual financial statements in its entirety are free from material misstatements, whether intentional or unintentional, and whether the management report as a whole provides a suitable view of the association's position and, in all significant respects, is consistent with the annual financial statements and the knowledge obtained in the audit, complies with the German legal requirements and adequately presents the opportunities and risks of future development, as well as to issue an auditor's report that includes our audit opinions on the annual financial statements and on the management report.

Sufficient certainty is a high level of certainty, but it is not a guarantee that an audit conducted in accordance with § 317 HGB and in compliance with German principles of proper auditing promulgated by the Institute of Public Auditors in Germany (IDW) will always detect a material misstatement. Misstatements can arise from infringements or inaccuracies and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial statements and this management report.

Throughout the audit, we exercise professional judgement and maintain a critical basic attitude. We also,

- identify and assess the risks of material misstatement, whether intentional or unintentional, in the annual financial statements and in the management report, plan and perform audit procedures responsive to those risks, and we gain audit evidence that is sufficient and appropriate to provide a basis for our audit opinions. The risk that material misstatements may not be exposed is greater in the event of infringements than in the event of inaccuracies, as infringements may involve collusion, forgery, intentional omissions, misrepresentation or the override of internal controls.
- gain an understanding of the internal control system relevant for the audit of the annual financial statements and the provisions and measures relevant for the audit of the management report in order to plan audit procedures that are appropriate in the given circumstances, but not for the purpose of expressing an audit opinion on the effectiveness of these systems of the association.
- evaluate the appropriateness of the accounting methods used by the Executive Committee and the justifiability of the estimates and related disclosures presented by the Executive Committee.

- conclude on the appropriateness of the Executive Committee's use of the going concern accounting principle and, based on the audit evidence obtained, whether material uncertainty exists related to events or circumstances that could raise significant doubts on the association's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in the auditor's report to the relevant disclosures in the annual financial statements and in the management report or, if such disclosures are inadequate, to modify our respective audit opinion. We draw our conclusions on the basis of the audit evidence obtained up to the date of our auditor's report. However, future events or circumstances may cause the association to cease to be able to continue as a going concern.
- evaluate the overall presentation, the structure and the content of the annual financial statements including the disclosures, and whether the annual financial statements present the underlying business transactions and events in a manner that the annual financial statements give a true and fair view of the net assets, financial position and results of operations of the association in accordance with German principles of proper accounting.
- evaluate the management report's consistency with the annual financial statements, its compliance with the German law, and the view of the association's position it provides.
- perform audit procedures on the forward-looking statements presented by the Executive Committee in the management report. On the basis of sufficient appropriate audit evidence we review, in particular, the significant assumptions used by the Executive Committee as a basis for the forward-looking statements, and evaluate the proper derivation of the forward-looking statements from these assumptions. We do not express a separate audit opinion on the forward-looking statements and on the underlying assumptions. There is a substantial unavoidable risk that future events will differ materially from the forward-looking statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in the internal control system that we identify during our audit.

Munich, 29 April 2022

Deloitte GmbH

Wirtschaftsprüfungsgesellschaft

Ralph Höll
Wirtschaftsprüfer
(German Public Auditor)

Sandro Süß
Wirtschaftsprüfer
(German Public Auditor)

